OralParenteralDosed ingredientTherapeutic flag Cosmetic cross-reference

Cholecalciferol

CAS 67-97-0

Cholecalciferol (CAS 67-97-0) is a Phase 4 pharmaceutical compound with 5 bioactivity targets and 17,331 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

17,331

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Cholecalciferol

CAS Number

67-97-0

UNII

1C6V77QF41

InChIKey

QYSXJUFSXHHAJI-YRZJJWOYSA-N

ChEMBL ID

CHEMBL1042

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoralparenteraltherapeutic flag

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1042 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 12 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	35689.73222222222 nM	82	-
-	AC50	25948.429032258067 nM	31	-
-	IC50	14767.48 nM	25	-
-	GI50	37825 nM	4	-
-	EC50	433.40333333333336 nM	3	-
-	Kd	1400 nM	1	-
Glycine receptor subunit alpha-1 Ion channel	EC50	6.4	-	Homo sapiens
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Enzyme	-	-	-	Homo sapiens
Vitamin D3 receptor Nuclear hormone receptor	EC50	9.68	-	Homo sapiens
Vitamin D 25-hydroxylase Enzyme	-	-	-	Homo sapiens
Sterol 26-hydroxylase, mitochondrial Enzyme	-	-	-	Homo sapiens
Vitamin D3 receptor Nuclear hormone receptor	EC50	6.05	-	Mus musculus

SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Toxicity to various agents	1433	2436.093	10070863
Completed suicide	253	2167.68	10010144
Drug abuse	255	1335.66	10013654
Pemphigus	5416	1127.988	10034280
Systemic lupus erythematosus	5898	1115.184	10042945
Death	6083	974.136	10011906
Glossodynia	5069	954.292	10018388
Drug interaction	2911	917.302	10013710
Alopecia	8108	895.263	10001760
Intentional overdose	234	859.888	10022523
Abdominal discomfort	8189	805.026	10000059
Rheumatoid arthritis	6701	800.002	10039073
Arthropathy	6118	756.143	10003285
Hand deformity	4363	741.061	10061194
Pain	16606	713.374	10033371
Overdose	1098	685.419	10033295
Wound	4481	669.271	10052428
Arthralgia	13378	609.293	10003239
Fatigue	20823	599.798	10016256
Maternal exposure during pregnancy	5111	587.471	10071408
Febrile neutropenia	1668	535.003	10016288
Joint swelling	7650	532.574	10023232
Suicide attempt	313	519.921	10042464
Cardiac arrest	1016	491.372	10007515
Swelling	6289	438.791	10042674
Acute kidney injury	4952	434.511	10069339
Depressed level of consciousness	412	428.834	10012373
Anti-cyclic citrullinated peptide antibody positive	2960	426.099	10068798
Discomfort	4125	421.523	10013082
Synovitis	4375	412.321	10042868
Hepatic function abnormal	269	401.677	10019670
Pericarditis	3332	378.622	10034484
Psoriatic arthropathy	2608	360.006	10037162
Drug resistance	132	358.137	10059866
Disease progression	1769	357.665	10061818
Contraindicated product administered	5061	356.155	10078504
Multiple organ dysfunction syndrome	746	344.832	10077361
Infusion related reaction	6034	336.835	10051792
Coma	580	332.686	10010071
Nasopharyngitis	6061	330.817	10028810
Femur fracture	1365	318.67	10016454
Respiratory arrest	181	317.731	10038669
Renal failure	1885	317.669	10038435
Sedation	205	312.668	10039897
Malignant neoplasm progression	1110	306.067	10051398
Neutropenia	2946	305.507	10029354
Drug reaction with eosinophilia and systemic symptoms	246	302.665	10073508
Musculoskeletal stiffness	4500	299.645	10052904
Cardio-respiratory arrest	635	298.642	10007617
Rhabdomyolysis	614	283.662	10039020

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR ligand-target interactions 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
Farnesoid X receptor-β Nr1h5	Agonist	5.0 pEC50	12529392

SOURCE RxNorm drug names 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
CHOLECALCIFEROL	2418	SU	MTHSPL
Cholecalciferol	2418	SU	MTHSPL
cholecalciferol	2418	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Cholecalciferol used for in pharmaceutical contexts?

Cholecalciferol (CAS 67-97-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Cholecalciferol?

Cholecalciferol has 17,331 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxicity to various agents, Completed suicide, Drug abuse, Pemphigus, Systemic lupus erythematosus. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Cholecalciferol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for CHOLECALCIFEROL with EU status "prohibited".

What clinical phase is Cholecalciferol in?

Cholecalciferol is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Cholecalciferol?

Cholecalciferol has 12 bioactivity rows in this page query. Rendered target entries include Glycine receptor subunit alpha-1, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor, Vitamin D 25-hydroxylase, Sterol 26-hydroxylase, mitochondrial.